Loading...
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
PURPOSE: To evaluate the cost-effectiveness of adding ribociclib to endocrine therapy for pre/perimenopausal women with hormone receptor-positive (HR+), human epidermal receptor 2-negative (HER2-) advanced breast cancer from the US payer perspective. METHODS: A partitioned survival analysis model wi...
Saved in:
| Published in: | Front Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Frontiers Media S.A.
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8138037/ https://ncbi.nlm.nih.gov/pubmed/34026637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.658054 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|